Embedded Files
Meet Dr. Matus Čoma: Advancing the Future of Pancreatic Cancer Research
In the rapidly evolving landscape of oncology, the quest to understand and defeat aggressive cancers remains one of the greatest scientific challenges of our time. International cancer conferences play a crucial role in this mission — they bring together brilliant minds, cutting-edge research, and transformative ideas that shape the future of cancer care. Among the distinguished experts participating in the 12th International Cancer, Oncology and Therapy Conference, scheduled in Dubai in April 2026, is one of Europe’s emerging scientific leaders: Dr. Matus Čoma.
A researcher from Pavol Jozef Šafárik University in Slovakia, Dr. Čoma has built an impressive scientific profile. From investigating the tumor microenvironment of pancreatic cancer to pioneering combination drug strategies, his work bridges molecular biology, pharmacology, and translational medicine…
A Researcher at the Forefront of Pancreatic Cancer Biology
Pancreatic cancer — especially pancreatic ductal adenocarcinoma (PDAC) — is notorious for its aggressiveness and late-stage diagnosis.
Dr. Čoma’s research focuses on understanding:
Why PDAC is resistant to treatment
How the tumor microenvironment and cancer-associated fibroblasts (CAFs) influence disease progression
How chemotherapy resistance develops
His academic journey spans chemistry, biochemistry, and pharmacology, supported by expertise at the Medical University of Graz.
Understanding the Complex Tumor Microenvironment
The tumor microenvironment (TME) in PDAC is dense and fibrotic due to desmoplasia, driven largely by cancer-associated fibroblasts.
Dr. Čoma’s work investigates how fibroblasts:
Shape cancer cell behavior
Promote drug resistance
Modify the extracellular matrix
Alter response to chemotherapy
His studies on PDAC cell lines revealed significant heterogeneity — a key insight proving that PDAC treatment cannot be one-size-fits-all.
Key Molecular Drivers Identified in His Research
Dr. Čoma identified several high-impact molecules involved in tumor–stroma interaction:
These biomarkers are essential for developing targeted cancer therapies and improving PDAC treatment outcomes.
Therapeutic Innovation: Repurposing Tigecycline for Pancreatic Cancer
One major highlight of his current work is repurposing tigecycline to enhance the cytotoxic effect of standard PDAC therapies:
Repurposing existing drugs can accelerate impactful clinical solutions, especially for cancers as resistant as PDAC.
Targeting the Tumor Microenvironment: A New Therapeutic Pathway
Traditional cancer therapies target only tumor cells, but PDAC requires a dual focus on the stroma.
Dr. Čoma’s VEGA-funded research explores:
These cutting-edge strategies are redefining PDAC treatment.
Achievements and Professional Recognition
Dr. Čoma has:
300+ citations
H-index of 10
PI of a national PDAC grant
Membership in the European Association for Cancer Research
His contributions are rapidly strengthening the global PDAC research ecosystem.
Why His Work Matters — A Bigger Picture
Pancreatic cancer is projected to become the second leading cause of cancer-related deaths globally.
This is due to:
Silent progression
Late diagnosis
Dense microenvironment
Treatment resistance
Researchers like Dr. Čoma are crucial to addressing these challenges and pioneering more effective pancreatic cancer treatments.
Why You Should Attend His Session at the 12th International Cancer, Oncology and Therapy Conference
1. Deep Scientific Insight
Learn about tumor–stroma crosstalk and PDAC molecular complexity.
2. Exposure to Cutting-Edge Therapeutics
Understand how drug repurposing like tigecycline can transform PDAC treatment.
3. Networking with Leading Scientists
Connect with global oncology specialists.
4. Educational Growth
Earn CME/CPD credits while advancing your clinical and scientific expertise.
5. Multidisciplinary Engagement
Meet leaders from oncology, pharmacology, immunology, and more.
Pancreatic cancer demands innovative, multidisciplinary approaches. Dr. Matus Čoma’s research — focusing on the tumor microenvironment, chemoresistance, and drug repurposing — stands at the frontier of PDAC discovery.
The 12th International Cancer, Oncology and Therapy Conference offers a unique opportunity to learn from his work and join global discussions shaping the future of cancer care.
If you are committed to advancing cancer research, this is a session you cannot miss.
Share Your Findings: https://cancer.utilitarianconferences.com/submit-abstract
Secure Your Spot: https://cancer.utilitarianconferences.com/registration
#CancerResearch #OncologyConference #PancreaticCancer #TumorMicroenvironment #Pharmacology #TranslationalMedicine #CancerTherapy #DrugRepurposing #StromaTargeting #UtilitarianConferences
Page updated
Google Sites
Report abuse